首页> 外文期刊>Natural product communications >Screening of Microbial Extracts for Anticancer Compounds Using Streptomyces Kinase Inhibitor Assay
【24h】

Screening of Microbial Extracts for Anticancer Compounds Using Streptomyces Kinase Inhibitor Assay

机译:使用链霉菌激酶抑制剂分析筛选抗癌化合物的微生物提取物

获取原文
获取原文并翻译 | 示例
           

摘要

Eukaryotic kinases are known to play an important role in signal transduction pathways by phosphorylating their respective substrates. Abnormal phosphorylations by these kinases have resulted in diseases. Hence inhibitors of kinases are of considerable pharmaceutical interest for a wide variety of disease targets, especially cancers. A number of reports have been published which indicate that eukaryotic-like kinases may complement two-component kinase systems in several bacteria. In Streptomyces sp. such kinases have been found to have a role in formation of aerial hyphae, spores, pigmentation & even in antibiotic production in some strains. Eukaryotic kinase inhibitors are seen to inhibit formation of aerial mycelia in Streptomyces without inhibiting vegetative mycelia. This property has been used to design an assay to screen for eukaryotic kinase inhibitors. The assay involves testing of compounds against Streptomyces 85E ATCC 55824 using agar well diffusion method. Inhibitors of kinases give rise to "bald" colonies where aerial mycelia and sporulation inhibition is seen. The assay has been standardized using known eukaryotic protein kinase inhibiting anticancer agents like AG-490, AG-1295, AG-1478, Flavopiridol and Imatinib as positive controls, at a concentration ranging from 10 mu g/well to 100 mu g/well. Anti-infective compounds which are not reported to inhibit eukaryotic protein kinases were used as negative controls. A number of microbial cultures have been screened for novel eukaryotic protein kinase inhibitors. Further these microbial extracts were tested in various cancer cell lines like Panc1, HCT116, Calu1, ACHN and H460 at a concentration of 10 mu g/mL/ well. The anticancer data was seen correlating well with the Streptomyces kinase assay thus validating the assay.
机译:已知真核激酶通过使它们各自的底物磷酸化而在信号转导途径中起重要作用。这些激酶的异常磷酸化已导致疾病。因此,激酶抑制剂对于多种疾病靶标,特别是癌症具有重要的药学意义。已经发表了许多报告,这些报告表明真核样激酶可以补充几种细菌中的双组分激酶系统。在链霉菌中。已经发现这种激酶在某些菌株中在气生菌丝,孢子,色素沉着甚至抗生素产生中起作用。真核激酶抑制剂被认为可以抑制链霉菌中气生菌丝的形成,而不会抑制植物菌丝。此属性已用于设计筛选真核激酶抑制剂的检测方法。该测定涉及使用琼脂井扩散法测试化合物对链霉菌85E ATCC 55824的抵抗力。激酶抑制剂会引起“秃顶”菌落,在该处可见气生菌丝体和孢子形成抑制作用。已经使用已知的真核蛋白激酶抑制性抗癌药(例如AG-490,AG-1295,AG-1478,Flavopiridol和Imatinib)作为阳性对照进行了标准化,浓度范围为10μg/孔至100μg/孔。尚未报道抑制真核蛋白激酶的抗感染化合物被用作阴性对照。已经筛选了许多微生物培养物中的新型真核蛋白激酶抑制剂。此外,这些微生物提取物在各种癌细胞系(如Panc1,HCT116,Calu1,ACHN和H460)中以10μg / mL /孔的浓度进行了测试。观察到抗癌数据与链霉菌激酶测定具有很好的相关性,从而验证了该测定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号